Keros Therapeutics, Inc. Banner Image

Keros Therapeutics, Inc.

  • Ticker KROS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Keros Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Lexington, Massachusetts
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. They are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of bloodMore cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, they have discovered and are developing large and small molecules that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Keros’ third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ fourth product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on DMD.
Keros Therapeutics, Inc.

Most Recent Annual Report

Keros Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Keros Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!